COMPARISON
Abaloparatide vs Teriparatide
7 attributes held for at least one of the two. 6 differ. Each value carries the register it came from and the date that register was read.
Answer
Abaloparatide is authorised or registered in 5 and Teriparatide in 10 of the 10 registers read. Abaloparatide: No trial states a phase. Teriparatide: highest phase Phase 4 (after approval). 5 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Abaloparatide | Teriparatide | |
|---|---|---|
| Registered trials differs | 25 clinicaltrials.gov · 2026-10-03 | 185 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Tymlos openfda · 2026-10-03T17:23:44.062Z | FDA-approved: teriparatide openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2022-12-12 ema · 2026-10-03 | 2003-06-10 ema · 2026-10-03 |
| EU refused on differs | 2018-04-03 ema · 2026-10-03 | Not checked no record of "refusedOn" for teriparatide |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for abaloparatide | 2020-11-24 ema · 2026-10-03 |
| ATC code differs | H05AA04 ema · 2026-10-03 | H05AA02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Abaloparatide | placebo | Teriparatide | placebo |
|---|---|---|---|---|
| Hypercalciuria | 9.7% | 8.9% | 11.3% | 6.7% |
| Dizziness | 9.4% | 5.5% | 6.8% | 5.2% |
| Nasopharyngitis | 8.8% | 8.5% | 14.1% | 13.4% |
| Arthralgia | 8.3% | 9.3% | 9.1% | 9.2% |
| Nausea | 8.0% | 3.1% | 6.3% | 3.8% |
| Headache | 7.2% | 6.1% | 7.6% | 6.5% |
| Back pain | 7.1% | 8.2% | 9.5% | 10.2% |
| Upper respiratory tract infection | 6.9% | 7.8% | 7.0% | 5.6% |
| Hypertension | 6.2% | 6.0% | - | - |
| Influenza | 5.8% | 4.5% | - | - |
| Pain in extremity | - | - | 6.0% | 5.2% |
| Constipation | - | - | 5.3% | 4.5% |
Trial register Abaloparatide: 4 placebo-controlled trials; Teriparatide: 11. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Abaloparatide side effects · Teriparatide side effects
LEGAL STATUS
Approval in each country read
| Country | Abaloparatide | Teriparatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
5 registered trials include both
| NCT06164795 | Sequential Therapies After Osteoanabolic Treatment RECRUITING · updated 2026-07-22 |
|---|---|
| NCT06898060 | To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture NOT_YET_RECRUITING · updated 2025-03-27 |
| NCT04974723 | Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women COMPLETED · updated 2024-04-19 |
| NCT00542425 | Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis COMPLETED · updated 2017-10-30 |
| NCT01343004 | Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women COMPLETED · updated 2017-03-01 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.